Top Markets
Coin of the day
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
Classement en actions #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Prix de l'action
$1.81
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$77.00M
Changement (1 jour)
1.30%
Changement (1 an)
-23.63%
Pays
US
Échange Annovis Bio, Inc. (ANVS)

Catégorie

Historique du rendement du dividende pour Annovis Bio, Inc. (ANVS)
Le rendement du dividende (TTM) de Annovis Bio, Inc. (symbole boursier : ANVS) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Annovis Bio, Inc. (ANVS) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH